Ipsen S.A.

Ipsen S.A. is a global biopharmaceutical group dedicated to improving lives through innovative medicines in oncology, neuroscience, and rare diseases. As a specialized player in the pharmaceutical industry, Ipsen develops and markets pharmaceuticals that cater to critical areas of unmet medical needs. Its oncology segment focuses on therapies for cancers such as neuroendocrine tumors and prostate cancer. In neuroscience, Ipsen addresses disorders affecting nervous system functions, including muscular issues like spastic diplegia. The rare diseases division emphasizes conditions that lack adequate treatment options, often collaborating with research entities to enhance therapeutic development. Founded in 1929 and based in France, Ipsen operates with a strong international presence, engaging in research and development activities across multiple regions. By prioritizing patient-centric approaches and continuous innovation, Ipsen plays a significant role in advancing healthcare outcomes, addressing complex medical challenges, and contributing to the global pharmaceutical industry landscape.